These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 26842854)

  • 1. Small-molecule CFTR activators increase tear secretion and prevent experimental dry eye disease.
    Flores AM; Casey SD; Felix CM; Phuan PW; Verkman AS; Levin MH
    FASEB J; 2016 May; 30(5):1789-97. PubMed ID: 26842854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanomolar-Potency Aminophenyl-1,3,5-triazine Activators of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Channel for Prosecretory Therapy of Dry Eye Diseases.
    Lee S; Phuan PW; Felix CM; Tan JA; Levin MH; Verkman AS
    J Med Chem; 2017 Feb; 60(3):1210-1218. PubMed ID: 28099811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanomolar Potency Aminophenyltriazine CFTR Activator Reverses Corneal Epithelial Injury in a Mouse Model of Dry Eye.
    Chen X; Lee S; Zhang T; Duan T; Pasricha ND; Schallhorn JM; Levin MH; Koprivica V; Verkman AS
    J Ocul Pharmacol Ther; 2020 Apr; 36(3):147-153. PubMed ID: 31934802
    [No Abstract]   [Full Text] [Related]  

  • 4. Pro-Secretory Activity and Pharmacology in Rabbits of an Aminophenyl-1,3,5-Triazine CFTR Activator for Dry Eye Disorders.
    Felix CM; Lee S; Levin MH; Verkman AS
    Invest Ophthalmol Vis Sci; 2017 Sep; 58(11):4506-4513. PubMed ID: 28873176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isorhamnetin Ameliorates Dry Eye Disease via CFTR Activation in Mice.
    Lee HK; Park J; Kim BR; Jun I; Kim TI; Namkung W
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential difference measurements of ocular surface Na+ absorption analyzed using an electrokinetic model.
    Levin MH; Kim JK; Hu J; Verkman AS
    Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):306-16. PubMed ID: 16384978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel CFTR Activator Cact-3 Ameliorates Ocular Surface Dysfunctions in Scopolamine-Induced Dry Eye Mice.
    Jeon D; Jun I; Lee HK; Park J; Kim BR; Ryu K; Yoon H; Kim TI; Namkung W
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CFTR-regulated chloride transport at the ocular surface in living mice measured by potential differences.
    Levin MH; Verkman AS
    Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1428-34. PubMed ID: 15790911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease.
    Vijmasi T; Chen FY; Chen YT; Gallup M; McNamara N
    Mol Vis; 2013; 19():1957-65. PubMed ID: 24068863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic Strategies for Improving Solubility: Optimization of Novel Pyrazolo[1,5-
    Kim BY; Oh C; Jeon D; Jun I; Lee HK; Kim BR; Park J; Seo KY; Kim KA; Lim D; Lee S; Lee J; Yoon H; Kim TI; Namkung W
    J Med Chem; 2023 Jan; 66(1):413-434. PubMed ID: 36573286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Insight Into the Role of CFTR in Lacrimal Gland Duct Function in Mice.
    Berczeli O; Vizvári E; Katona M; Török D; Szalay L; Rárosi F; Németh I; Rakonczay Z; Hegyi P; Ding C; Tóth-Molnár E
    Invest Ophthalmol Vis Sci; 2018 Jan; 59(1):54-62. PubMed ID: 29305607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenylquinoxalinone CFTR activator as potential prosecretory therapy for constipation.
    Cil O; Phuan PW; Son JH; Zhu JS; Ku CK; Tabib NA; Teuthorn AP; Ferrera L; Zachos NC; Lin R; Galietta LJV; Donowitz M; Kurth MJ; Verkman AS
    Transl Res; 2017 Apr; 182():14-26.e4. PubMed ID: 27815136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye.
    Jain P; Li R; Lama T; Saragovi HU; Cumberlidge G; Meerovitch K
    Exp Eye Res; 2011 Oct; 93(4):503-12. PubMed ID: 21726552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical administration of lacritin is a novel therapy for aqueous-deficient dry eye disease.
    Vijmasi T; Chen FY; Balasubbu S; Gallup M; McKown RL; Laurie GW; McNamara NA
    Invest Ophthalmol Vis Sci; 2014 Jul; 55(8):5401-9. PubMed ID: 25034600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical TSG-6 Administration Protects the Ocular Surface in Two Mouse Models of Inflammation-Related Dry Eye.
    Lee MJ; Kim DH; Ryu JS; Ko AY; Ko JH; Kim MK; Wee WR; Khwarg SI; Oh JY
    Invest Ophthalmol Vis Sci; 2015 Aug; 56(9):5175-81. PubMed ID: 26244293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of Lipid Peroxidation Markers in the Tear Film and Ocular Surface of Patients with Non-Sjogren Syndrome: Potential Biomarkers for Dry Eye Disease.
    Choi W; Lian C; Ying L; Kim GE; You IC; Park SH; Yoon KC
    Curr Eye Res; 2016 Sep; 41(9):1143-9. PubMed ID: 26731289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preservation of tear film integrity and inhibition of corneal injury by dexamethasone in a rabbit model of lacrimal gland inflammation-induced dry eye.
    Nagelhout TJ; Gamache DA; Roberts L; Brady MT; Yanni JM
    J Ocul Pharmacol Ther; 2005 Apr; 21(2):139-48. PubMed ID: 15857280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of topically applied epithelial sodium channel inhibitors on tear production in normal mice and in mice with induced aqueous tear deficiency.
    Thelin WR; Johnson MR; Hirsh AJ; Kublin CL; Zoukhri D
    J Ocul Pharmacol Ther; 2012 Aug; 28(4):433-8. PubMed ID: 22455658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sjögren's syndrome associated dry eye in a mouse model is ameliorated by topical application of integrin α4 antagonist GW559090.
    Contreras-Ruiz L; Mir FA; Turpie B; Krauss AH; Masli S
    Exp Eye Res; 2016 Feb; 143():1-8. PubMed ID: 26463157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CFTR activator increases intestinal fluid secretion and normalizes stool output in a mouse model of constipation.
    Cil O; Phuan PW; Lee S; Tan J; Haggie PM; Levin MH; Sun L; Thiagarajah JR; Ma T; Verkman AS
    Cell Mol Gastroenterol Hepatol; 2016 May; 2(3):317-327. PubMed ID: 27127798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.